Nordea Investment Management AB Has $5.23 Million Stock Position in Doximity, Inc. $DOCS

Nordea Investment Management AB boosted its stake in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 28.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 85,439 shares of the company's stock after acquiring an additional 18,970 shares during the quarter. Nordea Investment Management AB's holdings in Doximity were worth $5,233,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Doximity by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company's stock worth $707,646,000 after acquiring an additional 990,923 shares during the last quarter. Invesco Ltd. grew its holdings in Doximity by 54.8% during the 1st quarter. Invesco Ltd. now owns 1,969,326 shares of the company's stock worth $114,280,000 after acquiring an additional 696,923 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Doximity by 130.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,966,801 shares of the company's stock worth $114,133,000 after acquiring an additional 1,113,076 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in shares of Doximity by 9.5% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,730,282 shares of the company's stock valued at $100,408,000 after purchasing an additional 150,574 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Doximity by 8.2% in the 1st quarter. Bank of New York Mellon Corp now owns 1,137,912 shares of the company's stock valued at $66,033,000 after purchasing an additional 86,135 shares during the last quarter. Institutional investors own 87.19% of the company's stock.

Doximity Price Performance

Doximity stock opened at $67.93 on Wednesday. The company's 50 day simple moving average is $69.46 and its 200 day simple moving average is $61.48. Doximity, Inc. has a fifty-two week low of $40.87 and a fifty-two week high of $85.21. The firm has a market capitalization of $12.72 billion, a price-to-earnings ratio of 67.93, a PEG ratio of 4.10 and a beta of 1.38.

Doximity (NASDAQ:DOCS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same quarter last year, the business posted $0.28 EPS. The firm's revenue was up 15.2% compared to the same quarter last year. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, analysts predict that Doximity, Inc. will post 0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Doximity news, Director Kira Scherer Wampler sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $57.09, for a total transaction of $114,180.00. Following the sale, the director directly owned 16,618 shares in the company, valued at approximately $948,721.62. This trade represents a 10.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $75.00, for a total transaction of $1,500,000.00. Following the sale, the director owned 3,221 shares in the company, valued at $241,575. This trade represents a 86.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,000 shares of company stock worth $2,635,880. Company insiders own 31.30% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group set a $64.00 target price on shares of Doximity and gave the company a "sell" rating in a research note on Wednesday, October 1st. Wells Fargo & Company raised their target price on shares of Doximity from $55.00 to $62.00 and gave the company an "equal weight" rating in a research note on Monday, August 4th. Evercore ISI raised their target price on shares of Doximity from $75.00 to $81.00 and gave the company an "outperform" rating in a research note on Wednesday, October 8th. Truist Financial raised their target price on shares of Doximity from $52.00 to $61.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. Finally, Robert W. Baird raised their target price on shares of Doximity from $75.00 to $80.00 and gave the company an "outperform" rating in a research note on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Doximity currently has a consensus rating of "Hold" and a consensus price target of $69.37.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.